Business
Lattice Biologics Extends Private Placement
Lattice Biologics Extends Private Placement.
About this update from Lattice Biologics Ltd
[{"type":"text","content":"\nLattice Biologics Extends Private Placement\n\nLattice Biologics Extends Private Placement\n\nSCOTTSDALE, AZ--(Marketwired - March 07, 2017) - NOT FOR DISSEMINATION IN THE US OR THROUGH US NEWSWIRE SERVICESLattice Biologics Ltd. (TSX VENTURE: LBL) (OTCQB: LBLTF) (\"Lattice Biologics\" or the \"Company\") announces that it is extending its non-brokered private placement of Units of the Company (\"Units\"), announced on January 19, 2017 (the \"Offering\"), for an additional 30 days.Each Unit consists of one common share in the capital stock of the Company (a \"Common Share\") and one-half of a common share purchase warrant (a \"Warrant\"). Each whole Warrant is exercisable into an additional Common Share at a price of Can$0.265 per Common Share for a period of 36 months from the date of issuance.To date, the Company has raised gross proceeds (including amounts announced on January 24, 2017, January 26, 2017, February 16, 2017 and February 28, 2017) of US$320,000 as part of the Offering.The net proceeds from the Offering will be used for general working capital, including to support increasing production of Lattice Biologics' recently launched amnion based products for the treatment of joint pain associated with osteoarthritis. Additionally, the funds raised will be utilized to launch new products, including next generation amniotic fluid products, and to support the Company's ongoing R&D efforts. Lattice Biologics has received conditional approval for the Offering from the TSX Venture Exchange.Lattice Biologics Ltd.Guy Cook,Chief Executive OfficerTelephone No: (480) 563-0800About Lattice Biologics Ltd.:Lattice Biologics Ltd. is an emerging precision medicine leader in the field of cellular therapies and tissue engineering, with an emphasis on bone, skin, and cartilage regeneration. As a manufacturer of the highest quality allografts, Lattice is focused on next generation products to improve surgical outcomes.Versatile allografts for a variety of surgical applications:Enhancing fusion in spine surgeryEnhancing breast reconstruction post mastectomy for breast cancer patientsSports medicine indications, including ACL repairPromotion of bone regeneration in foot and ankle surgeryPromotion of cranial healing following neurosurgeryEnhancing wound repair in burn victimsSubchondral bone defect repair in knee and other joint surgerie...